The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Real-world FIL-MAB data support frontline Pola-R-CHP in DLBCL
Marco Ladetto, MD, Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy, discusses the primary analysis of the polatuzumab vedotin plus R-CHP (Pola-R-CHP) cohort from FIL-MAB (NCT06008691), a prospective, multicenter Italian real-world study. He highlights findings from one of the largest real-life evaluations of frontline Pola-R-CHP in diffuse large B-cell lymphoma (DLBCL), demonstrating encouraging effectiveness, a manageable safety profile, and broad applicability across both academic and community treatment centers. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
